The Cellularis Discovery by Early Sight
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- Points of contact
-
- CDRH Acquisition Liaison cdhracquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration (FDA) is forecasting a new requirement to procure The Cellularis Discovery by Early Sight, a commercial clinical adaptive optics (AO) retinal camera system. This procurement supports the FDA's Ophthalmic Devices Program by enabling the development of new cellular imaging biomarkers and advancing clinical translation of innovative medical device technology. The estimated solicitation release date is May 1, 2026, with an anticipated award date of June 1, 2026.
The estimated contract award value ranges from $25,000 to $250,000, with the requirement classified under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing). Prospective contractors should direct inquiries to the FDA's acquisition mailbox at cdhracquisitions@fda.hhs.gov. No set-aside provisions have been designated for this opportunity.
Forecast text
The Cellularis Discovery by Early Sight is one of the first commercial clinical AO retinal cameras. It will be used to advance the development of new cellular imaging biomarkers for the Ophthalmic Devices Program. In particular, many new methods and tools will be developed using this system. It fulfills the FDA mission to foster clinical translation of innovative medical device technology.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast